RxDoctor Payments Data

Brad Greenfield, MD

Radiation Oncology · Pascagoula, MSNPI 1336431436

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $168 and has fallen 55.0% since, to $75 in 2025. That places this record below the midpoint for radiation oncology clinicians in MS, where the typical reported total is $476.

$423in general payments, 2019–2025

Across 25 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$74
  • Bristol Myers Squibb$41
  • Boston Scientific$38
  • Ipsen Biopharmaceuticals, Inc$36
  • Incyte Corporation$36
  • Medtronic$35
  • plus $161 from 9 others

What the payments were for

  • Food & beverage$423100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$423 in reported general payments places this provider in the 45th percentile of 36 radiation oncology providers in Mississippi.

See all radiation oncology providers in Mississippi

Medicare billing

Part B allowed, 2024
$130,741
Medicare patients
120
Services billed
1,572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix12$32,537
Lorazepam13$13

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Pascagoula

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →